Search

Your search keyword '"Ceferino Barbazán-Álvarez"' showing total 2 results
Start Over Author "Ceferino Barbazán-Álvarez"
2 results on '"Ceferino Barbazán-Álvarez"'

1. Analysis of the implementation of an innovative IT solution to improve waiting times, communication with primary care and efficiency in Rheumatology

Author

José María Pego-Reigosa, Carlos Peña-Gil, David Rodríguez-Lorenzo, Irene Altabás-González, Naír Pérez-Gómez, John Henry Guzmán-Castro, Rodrigo Varela-Gestoso, Reyes Díaz-Lambarri, Alberto González-Carreró-López, Olga Míguez-Senra, Julia Bóveda-Fontán, Ángeles Charle-Crespo, Francisco Javier Caramés-Casal, Ceferino Barbazán-Álvarez, Íñigo Hernández-Rodríguez, Francisco Maceiras-Pan, Marina Rodríguez-López, Rafael Melero-González, and José Benito Rodríguez-Fernández

Subjects
Rheumatic diseases, Implementation, Early diagnosis, Telemedicine, Medical informatics, Needs assessment, Public aspects of medicine, RA1-1270
Abstract

Abstract Objective To describe in detail an innovative program based on telemedicine for semi-automated prioritization of referrals from Primary Care (PC) to Rheumatology, for reproducibility purposes, and to present the results of the implementation study. Methods The context and situation were carefully analyzed, paying attention to all processes in place, referral numbers, waiting times, and number of complementary tests prior to discharge from Rheumatology. The composition of the team, aims, users, scope, and implementation phases were defined. Eight process indicators were established and measured before and 32 months after the program implementation. Results The program, which includes IT circuits, algorithms based on response to specific guideline-based checklists, e-consultation, and appointments based on priority, was fully implemented in our health area after a pilot study in two PC centers. After implementation, 6185 rheumatology referrals showed an e-consultation response delay of 8.95 days, and to first face-to-face visit (after e-consultation) of 12.6 (previous delay before program implementation was 83.1 days). Resolution by e-consultation reached 20% (1195 patients did not need seeing the rheumatologist to have the problem solved), and 1369 patients (32%) were discharged after the first visit. The overall resolution rate was 44.0% (2564 discharges/5830 e-consultations). From a random sample of 100 visits, only 10% of patients needed additional complementary tests to make a diagnosis and decision by Rheumatology (20.9% decrease from previous period). Conclusion A careful analysis of the situation and processes, with implementation of simple IT circuits, allows for the improvement of the efficiency and resolution of problems in Rheumatology.

Published
2022
Full Text
View/download PDF

2. Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study

Author

Antonio Gómez-Centeno, Santiago Muñoz-Fernández, Ceferino Barbazán-Álvarez, Sagrario Bustabad, Sara Manrique-Arija, Esteban Rubio-Romero, Juan Amarelo-Ramos, Juan Ovalles, Javier del Pino-Montes, and Sara Marsal-Barril

Subjects
Adult, Male, medicine.medical_specialty, Immunology, Disease, Arthritis, Rheumatoid, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Quality of life, Internal medicine, Humans, Immunology and Allergy, Medicine, Registries, 030212 general & internal medicine, Aged, Retrospective Studies, 030203 arthritis & rheumatology, Biological Products, business.industry, Medical record, Middle Aged, medicine.disease, Methotrexate, Treatment Outcome, Antirheumatic Agents, Rheumatoid arthritis, Concomitant, Cohort, Quality of Life, Drug Therapy, Combination, Female, Observational study, business
Abstract

To describe the clinical and therapeutic management of rheumatoid arthritis (RA) patients with biological disease-modifying antirheumatic drugs (bDMARDs), alone or in combination with conventional synthetic DMARDs (csDMARDs), as well as analysing changes over time in bDMARD use. An observational, retrospective, multicentre study was conducted in the rheumatology departments of 10 public Spanish hospitals. Patients with RA treated with bDMARDs at baseline who had medical records available in the data collection period 2013-2016 were included. All visits to rheumatology departments recording any type of bDMARD modification (dose, etc.) were collected. Clinical characteristics, concomitant treatment, resource use, work productivity and quality of life (QoL) were recorded. 128 patients were included: 81 received first-line bDMARD treatment, 28 second-line bDMARD treatment and 19 received third or later lines. Mean study follow-up was 4.1 years. Assessment of DAS28 was available in 54.6% of visits. At baseline, 48.7% of patients had moderate-high disease activity. At final observation, 69.5% of patients continued with the first bDMARD. Tumour necrosis factor blockers were administered to 85.2% of patients in first line, 45.7% in second line and 18.1% in third or later lines. At final observation, 80.2% of patients still felt pain/discomfort. As expected, those with higher disease activity had higher loss of work productivity and lower QoL, as assessed by DAS28, than patients with lower disease activity. Drugs represented 82.6% of the total cost. In this Spanish cohort of 128 patients, most patients remained on the first prescribed bDMARD, despite remaining signs and symptoms.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results